Navigation Links
AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
Date:6/15/2009

The third study in the Phase 3 program, a multi-center safety study, for which patient recruitment was completed in December 2008, is an ongoing open-label, single-armed study involving 528 patients in North America. The lead investigator is Joel Kaufman, M.D., Associate Clinical Professor in Urology at University of Colorado School of Medicine in Denver, Colorado and at Urology Research Options in Aurora, Colorado.

First efficacy results are expected during the third quarter of 2009 with an NDA filing targeted in 2010.

Recently, AEterna Zentaris also announced that patients completing two years of therapy with cetrorelix in the first efficacy study (study 033), will be eligible to continue with the cetrorelix treatment, according to treatment regimen of the ongoing Phase 3 study, until the end of 2011. Patients entering this extension study sponsored by the Company's partner sanofi-aventis, will be followed-up for safety, International Prostate Symptom Score (IPSS) and quality of life during the extended treatment, providing follow-up data on cetrorelix for up to 5 years.

About Cetrorelix

Cetrorelix pamoate is an investigational agent that has shown in Phase 2 studies to provide fast and long lasting relief of BPH symptoms and was well tolerated, with a low incidence of sexual side effects. Cetrorelix is part of AEterna Zentaris' luteinizing hormone-releasing hormone (LHRH) antagonist therapeutic approach. This peptide-based active substance was developed by the Company in cooperation with Nobel Prize winner Prof. Andrew Schally, currently of the U.S. Veterans Administration in Miami.

Cetrorelix acetate is marketed under the brand name Cetrotide(R), the first LHRH antagonist approved for therapeutic use as part of in vitro fertilization programs (controlled ovulation stimulation/assisted reproductive technologies) in Europe, the USA and Japan. It was launched on the market through Serono (now
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
2. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
3. AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130
4. AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
5. AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting
6. AEterna Zentaris to Announce First Quarter 2009 Financial and Operating Results and Hold Annual Shareholder Meeting on May 6, 2009
7. AEterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
8. AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
9. AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting
10. AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting
11. AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Earlier this year in a June 24 international ... Adult Stem Cell Technology Center, LLC ( ASCTC ) ... unique property of adult tissue stem cells. His ... the Past, Important for the Future,” embodied the essence ... the address at the 4th World Congress on Cell ...
(Date:12/24/2014)... 2014 The report provides ... its definition, classification, application and industry overview. ... process, and product cost structure. Production is ... analysis also covers upstream raw materials, equipment, ... trend and proposals. In the end, the ...
(Date:12/24/2014)... -- China Biologic Products, Inc. (NASDAQ: CBPO, "China ... plasma-based biopharmaceutical company in China ... Taibang Biological Products Co. Ltd., has received Good ... and Drug Administration (the "CFDA") for its new ... the Company,s public filings, the CFDA inspected this ...
(Date:12/24/2014)... Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... filed a Clinical Trial Application (CTA) with the ... Agency (MHRA) seeking regulatory approval to initiate clinical trials ... Citrate. Contingent on the Company receiving CTA ... I trial to assess the safety, tolerability and dose ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... ... listed below, ST. LOUIS, June 13 ETHEX Corporation announced ... mg extended release tablets, and specific lots of morphine,sulfate 30 mg ... oversized tablets. Oversized tablets may contain as,much as two times the ...
... Conn., June 13 Alexion,Pharmaceuticals, Inc. (Nasdaq: ... President and Chief Financial Officer of Alexion,Pharmaceuticals, will ... Stock,Conference in Chicago at 9:10 a.m., local time ... An audio webcast of Mr. Sinha,s remarks will ...
... 13 Best Practices, LLC,s latest,benchmarking study explains ... CI operations while working within defined,guidelines., Particular ... is being,collected, and how CI groups work within ... collection that are in the best interests of,the ...
Cached Biology Technology:ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets 2ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets 3ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets 4Pharmaceutical Competitive Intelligence Excellence: Optimizing Data Collection with Approved Guidelines 2
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
(Date:12/3/2014)...   Marvin Test Solutions , a trusted ... military, aerospace, and manufacturing organizations, today announced the ... TS-900 PXI semiconductor test platform . The TS-960 ... to customers at a fraction of the footprint ... "Our semiconductor customers asked for ...
(Date:11/21/2014)... MOUNTAIN VIEW, Calif. , Nov. 20, 2014 /PRNewswire/ ... for higher driver efficiency are piloting the North American ... the number of accidents growing, gesture recognition systems that ... will make a mark in the industry. ... of the Automotive Gesture Recognition Market in ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... available amount of fossil fuels is limited and their ... The generation of fuels from biomass as an alternative ... Chemie , Johannes A. Lercher and his team at ... catalytic process that allows the effective conversion of biopetroleum ...
... KAN. -- A Kansas State University graduate student sees the ... Smith, master,s student in civil engineering, Independence, Mo., is working ... to improve the quality of unpaved roads throughout Kansas. ... in Kansas are unpaved, Smith said. "One of the ...
... advancing field of tissue injury and repair has an ... will report the latest research findings, innovative wound care ... skin and tissue regeneration to optimize patient outcomes. The ... is an Official Publication of the Wound Healing ...
Cached Biology News:Algae for your fuel tank 2The path less traveled: Research is driving solutions to improve unpaved roads 2The path less traveled: Research is driving solutions to improve unpaved roads 3New publication fosters improved wound care for ulcers, limb salvage, burns, trauma, and more 2
Sheep polyclonal to Melatonin ( Abpromise for all tested applications). Antigen: Melatonin Tg conjugate....
Goat anti-PITPN Class: Antibody Product Group: Miscellaneous Antibody...
COMING SOON: Anti-Mouse CD205 (DEC-205),Clone NLDC-145, mAb...
Anti-MT3-MMP Membrane-Type Metalloproteinase-3; propeptide domain; rabbit host...
Biology Products: